How German media wound up misrepresenting the AstraZeneca jab
Political briefings - not facts and figures - may explain ‘incorrect’ claims
The German newspaper behind widely denied reports that the Oxford-AstraZeneca vaccine is only 8% effective in over-65s has doubled-down on its claims.
After the story was denied by both the German Health Ministry and the drug’s maker, Handelsblatt published a second article, headlined “controversy over AstraZeneca vaccine”, repeating “concerns about a low level of protection among seniors”. The story was also amplified by German tabloid Bild, which claimed the efficacy of the drug among over-65s was “less than 10%”, also citing anonymous sources.
Attributing the claims to a “multiple sources familiar with the German vaccination policy”, the journalist behind the Handelsblatt story has tweeted that the story is “a sourced piece of (political) reporting”, suggesting that it is not based on data seen by the paper.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
AstraZeneca chief executive Pascal Soriot has denied the story in no uncertain terms, telling La Repubblica that “it’s incorrect… I don't know where these numbers come from”. Calling for people to “really focus on the details and focus on the regulators”, Soriot added: “There may also be local political considerations sometimes?”
And this is where the cracks within Handelsblatt’s reporting may be explained.
Writing in the New Statesman, international correspondent Ido Vock notes that the report “emerged as a political story, briefed from political sources”. In other words, the Handelsblatt stories appear to be based not on facts and figures, “but briefings and counter-briefings from anonymous sources” that risk “muddying the waters by throwing around incendiary claims”.
In normal political coverage, basing stories on anonymous briefings is standard practice. But “the virus is not a political story suited to the palace intrigue of political journalism”, Vock says. “It is a medical story, and data such as the efficacy of a vaccine is not determined by government deliberation.”
In Handelsblatt’s follow-up story, published by last night, an anonymous source denied claims by the head of the European Medicines Agency and the German government that the report had confused the proportion of elderly people involved in clinical trials of the vaccine and its effectiveness among those age groups.
“Confusing the numbers is impossible,” the source reportedly said,
But more anonymous briefings - and no solid figures - have done little to diffuse the suggestion that the original story “was a load of cobblers”, says Politico’s Alex Wickham.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Joe Evans is the world news editor at TheWeek.co.uk. He joined the team in 2019 and held roles including deputy news editor and acting news editor before moving into his current position in early 2021. He is a regular panellist on The Week Unwrapped podcast, discussing politics and foreign affairs.
Before joining The Week, he worked as a freelance journalist covering the UK and Ireland for German newspapers and magazines. A series of features on Brexit and the Irish border got him nominated for the Hostwriter Prize in 2019. Prior to settling down in London, he lived and worked in Cambodia, where he ran communications for a non-governmental organisation and worked as a journalist covering Southeast Asia. He has a master’s degree in journalism from City, University of London, and before that studied English Literature at the University of Manchester.
-
Airplane food is reportedly getting much worse
Cockroaches and E. coli are among the recent problems encountered in the skies
By Justin Klawans, The Week US Published
-
What Mike Huckabee means for US-Israel relations
In the Spotlight Some observers are worried that the conservative evangelical minister could be a destabilizing influence on an already volatile region
By Rafi Schwartz, The Week US Published
-
Crossword: November 19, 2024
The Week's daily crossword
By The Week Staff Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published
-
Long Covid and chronic pain: is it all in the mind?
The Explainer 'Retraining the brain' could offer a solution for some long Covid sufferers
By The Week UK Published